Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited
Accelerates Asia Pacific expansion by acquiring a ready-built regional commercial platform with 14 marketed chronic disease products Aggregate consideration of USD250,000,000 (approximately RMB1,721,650,000), payable in three installments Delivers...
Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study
Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply Several combination treatment studies containing BRII-179 have quickly started to carry forward the Company's strategy for HBV...